

Keine Tauschexemplare, da auch
als elektronische Version vorhanden.

**Molecular diagnosis and pathogenesis of Marfan
syndrome and related heritable diseases associated
with thoracic aortic aneurysms and dissections**

Von der Naturwissenschaftlichen Fakultät der Gottfried
Wilhelm Leibniz Universität
Hannover
zur Erlangung des Grades

**Doktorin der Naturwissenschaften,
Dr.rer.nat**

genehmigte Dissertation

von

M.Sc. Ushanthine Kathiravel
geboren am 24.08.1982 in Sri-Lanka

2014

Table of Contents

Declaration..... *ii*

Dedication *iii*

Acknowledgement..... *iv*

Abstract..... *v*

Zusammenfassung *viii*

Table of Contents..... *xii*

Abbreviations..... *1*

List of Figures *1*

List of Tables *1*

1. Introduction..... **3**

1.1 Marfan syndrome **3**

 1.1.1 Clinical characteristics of Marfan syndrome 3

 1.1.2 Classification of aortic aneurysms and dissections 5

 1.1.3 Clinical diagnosis of Marfan syndrome 6

1.4 Molecular genetics of MFS **9**

1.2 Differential Diagnosis **11**

 1.2.1 Loeys-Dietz syndrome 12

 1.2.2 Vascular form of Ehlers-Danlos syndrome (vEDS)..... 13

 1.2.3 Arterial Tortuosity Syndrome (ATS) 13

 1.2.4 Non-syndromic familial Thoracic aortic aneurysms and dissections..... 14

 1.2.5 Thoracic aortic aneurysms and dissections in conjunction with bicuspid aortic valve 14

1.3 Molecular pathogenesis of TAAD in MFS and MFS-related diseases..... **15**

 1.3.1 VSMCs 16

 1.3.2 Collagen 17

 1.3.3 Elastin..... 17

 1.3.4 Fibrillin..... 17

Table of contents

1.4	Today's conflict in clinical and molecular diagnosis of Marfan and Marfan-related cardiovascular diseases	18
2.	<i>Aim of this study</i>.....	19
3.	<i>Materials and Methods</i>	20
3.1	Chemicals and Reagents	20
3.2	Biological Substances and Enzymes.....	21
3.3	Buffer and standard working solutions	21
3.4	Kits and protocols	22
3.5	Data Analysis Software and custom guide	23
3.6	Consumable Materials	23
3.7	Equipments.....	24
3.8	Candidate Gene Reference Accession IDs.....	25
3.9	In silico programs and commercial Database.....	25
3.10	Proband recruitment and group design for the validation of a novel large-scale sequencing microarray	26
3.10.1	Probands selection for further studies	27
3.11	Extraction of genomic DNA from whole blood and human tissue.....	28
3.12	Determination of genomic DNA concentration.....	29
3.13	Separation of nucleic acids by agarose gel electrophoresis.....	29
3.14	Short range Polymerase Chain Reaction.....	31
3.14.1	PCR Composition and Thermal Conditions of short range PCR.....	31
3.15	Conventional Sanger Sequencing Reaction.....	32
3.15.1	Sequence Set Up and Thermal Cycling Condition.....	33
3.16	Multiplex ligation-dependent probe amplification	35
3.16.1	MLPA assay	36
3.17	Refinement of deletion breakpoints using high resolution a-CGH and breakpoint spanning PCR	37
3.17.1	a-CGH assay	38
3.18	Linkage analysis using polymorphic microsatellite markers	39

Table of contents

3.18.1	Indirect DNA marker analysis in two German families.....	39
3.18.2	Marker selection.....	40
3.18.3	Testing and optimization of TAAD DNA markers for linkage analysis.....	41
3.18.4	Sizing and Genotyping of DNA markers.....	42
3.19	Custom-based high-density MFSTAAD resequencing microarray (Affymetrix)	45
3.19.1	MFSTAAD microarrays.....	47
3.19.2	Target sequence and probe selection.....	48
3.19.3	Long range PCR assay.....	48
3.19.3.1	Testing of long range PCR assay kit.....	49
3.19.4	PicoGreen quantification, pooling and purification of PCR amplicons.....	49
3.19.4.1	Quantitation and pooling of PCR amplicons.....	50
3.19.5	Fragmentation.....	51
3.19.6	Labeling and Hybridization.....	52
3.19.7	Washing, staining and data scanning.....	52
3.19.8	Data acquisition and sequence data analysis.....	53
3.20	Characterization of novel DNA variants.....	53
3.20.1	<i>in silico</i> biometric verification of DNA variants.....	54
4.	Results.....	55
4.1	Selection of different cohorts.....	55
4.2	Results of the custom-based MFSTAAD microarray.....	55
4.2.1	Results of Long- Range PCR assays.....	55
4.2.1.1	KOD XL DNA polymerase Long Range PCR kit, Novagen.....	55
4.2.1.2	GoTaq Flexi DNA polymerase Long Range PCR kit, Promega.....	57
4.2.1.3	Expand LongRange dNTPack Long Range PCR kit, Roche.....	57
4.2.1.4	Qiagen LongRange PCR kit, Qiagen.....	58
4.2.1.5	Final selection of a LongRange PCR kit for further analysis.....	60
4.2.2	Analytical sensitivity of the custom-based MFSTAAD resequencing microarray	61
4.2.3	General performance characteristics of the MFSTAAD custom microarray of two different cohorts (retrospective and prospective).....	62
4.2.4	Mutation yield and false positive rate.....	63
4.2.5	Novel SNPs found with the MFSTAAD resequencing assay.....	72

Table of contents

4.2.6	Mutation segregation analysis of known and novel DNA variants.....	74
4.3	Results on the correlation between CMN and EF versus genetic predisposition	74
4.4	Correlation of young age versus mutation yield	75
4.5	Results of conventional Sanger sequencing analysis of the SMAD3 gene	76
4.6	Characterization of exact FBN1 gene deletion breakpoints in patients I1-I3....	77
4.7	Indirect DNA marker linkage analysis in family 1 with promiscuous skeletal features	81
4.8	Indirect DNA marker linkage analysis in family 2 with Marfan habitus and aortic aneurysm	82
5.	<i>Discussion</i>	84
5.1	Design of the novel “MFSTAAD” high density oligonucleotide based resequencing microarray	84
5.1.1	Benefits of long range PCR assay for target amplification.....	85
5.1.2	Evaluation of the general performance characteristics of the MFSTAAD resequencing microarray	85
5.1.3	Analytical Sensitivity of the MFSTAAD microarray	86
5.1.4	Evaluation of mutation yield of the MFSTAAD microarray	89
5.2	Reduced penetrance and variable expression of MYH11 p.T1558M	89
5.3	Evaluation of correlation of histopathological changes versus genetic predisposition to TAAD.....	90
5.4	Evaluation of the correlation of age versus genetic predisposition	92
5.5	Classic MFS caused by true haploinsufficiency of the FBN1 gene	93
5.6	Evaluation of indirect DNA marker analysis in two unrelated German families	96
5.7	Résumé.....	98
6.	<i>Appendix</i>	99
7.	<i>References</i>	124
	<i>Curriculum vitae</i>	138
	<i>Publications</i>	139

Table of contents

<i>Poster presentations</i>	139
<i>Official speech</i>	140